Loading...
A large, double-blind, controlled trial was designed to evaluate the relative benefits of calcium-blockers, ACE inhibitors, and alpha-blockers versus diuretics in older (minimum age, 55) hypertensive patients with at least 1 other coronary risk factor. Although the trial is intended to continue for 4 to 8 years, the alpha-blocker arm was stopped after a median follow-up of 3.3 years because of a significant increase in adverse events. The 24,335 patients in this arm were assigned to either the diuretic chlorthalidone (12.5 mg to 25 mg daily) or the alpha-blocker doxazosin (2 mg to 8 mg daily). Data comparing diuretic therapy with calcium-blocker or ACE-inhibitor therapy are forthcoming.
The primary outcome of fatal coronary heart disease or …